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ABSTRACT
Hypertension remains poorly controlled in Palestine. Improvement of its management will require an understanding of the patient characteristics and treatment factors associated with uncontrolled hypertension. A cross-sectional analysis using data from prevalence of hypertension study
in West Bank (N=2077) using two-stage stratified sampling method. We studied antihypertensive
medication use, comorbidity, and blood pressure measurements for 573 hypertensive patients in 3
different primary care settings across Palestine. We concomitantly conducted comprehensive patient interviews covering demographic and clinical factors. Mean age of the patients was 57.5 ± SD
9.7 years. The mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) were
149±12 mm Hg and 91.2±9 mm Hg (respectively). Only 33.2% (190/573) of patients had mean
blood pressure < 140/90 mm Hg during the study period. Those who are "uncontrolled" had high
systolic blood pressure rather than diastolic pressure (59 vs 41%; P<0.01). 60% of uncontrolled
hypertension found to be non-adherent to their drug regimen, 28% experience adverse effects and
56% were found to be on monotherapy. There was no statistically significant in difference in sex
distribution, marital status and educational level between controlled and uncontrolled hypertension.
Multivariate analysis revealed several independent predictors of poor hypertension control; being
on monotherapy regimen [OR=2.14, 95% CI 1.51-2.59], being obese BMI >25 [OR=1.80, 95% CI
1.44-2.46], being non adherence to antihypertensive drugs [OR=2.67, 95% CI 2.34-3.11] and older
age > 65 [OR=2.12, 95% CI1.78-2.86]. Hypertension remains poorly controlled in clinical Practice
in West Bank. Physicians should aggressively treat elevated systolic BP. A number of factors contribute to poor control of hypertension including Non-adherence to drug regimens, frustration with
treatment and obesity. Further identification of patients at risk of poor control can lead to targeted
interventions to improve management.
Keywords: Hypertension, Palestine, Risk Factors, Pharmacists.
BACKGROUND
High blood pressure (BP), including prehypertension, is a major global health economic issue, accounting for about half of the
total cases of stroke and ischemic heart disease. It is responsible for about 7.6 million
deaths each year and costs over 92 million
disability-adjusted life years, both of which
represent 13.5 and 6.0% of the respective
global total in the year 2001 (1-2). The risk
factors of uncontrolled hypertension are well
documented; these include clinical events
such as myocardial infarction, stroke and
end-stage renal disease. Recent studies sug

gest that hypertension and its complications
constitute a health issue in Palestine. Studies
that evaluated cause-specific mortality and
hospitalization discharge diagnoses as well as
clinical observation support such observation
(3-6). Despite proven benefits of antihypertensive drugs in reducing blood pressure and events such as stroke and coronary
heart disease (7-11), the problem of uncontrolled hypertension is enormous. Data in the
literature suggested that 79% of people with
hypertension do not have their blood pressure
under control (12). The Third National
Health and Nutrition Survey in the United
States showed that only 14-25% of treated
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hypertensive adults had achieved effective
blood pressure control of <140/90 mmHg
(13].In Palestine, the most recent data on hypertension by the Palestinian Hypertension
Project (PHP) showed a prevalence rate of
27.6% (14). The Palestinian Hypertension
Project is a joint project between Al-Quds
University and Palestinian Ministry of
Health, supported by Palestinian American
Research Council (PARC). The percentage of
blood pressure control in Palestine was ranging from 27% - 40% in different primary
care centers (14), which can be improved by
pharmacological means and modifications of
life style (15). The study evaluated the role of
socio-economic factors including age in control of blood pressure. In addition, the study
measured patient awareness of desired target
blood pressure and importance of blood pressure control. These points were not as extensively examined in Palestine by other studies
(16). Second, the relationship between comorbidity and blood pressure control were
explored. Third, the relationship between
perceived adverse drug effects and influence
blood pressure control were explored, because patients with side effects may be less
likely to take their medications as directed
(17).
METHODS
STUDY PARTICIPANTS
The study design was a cross-sectional
survey conducted in the West Bank, Palestine. The estimated population of the West
Bank is slightly more than 2 million and has
a land area of 5640 km2 (including East Jerusalem) according to the official Palestinian
census of 2011(18). Quite a bit of heterogeneous can be found in the Palestinian population in terms of social classes, dietary habits
and living area (urban versus rural). Such
heterogeneity underscores the need to survey
representative samples of these groups, and
provides an opportunity to examine the effect
of environmental risk factors on the risk of
hypertension and related complications.
Three main governorates, Nablus (north),
Ramallah (center) and Hebron (south) of the
West Bank, were evaluated with one rural

and one urban Palestinian community in
each, between May 2011 and December
2011.Two-stage stratified sampling method
was used to select a representative sample of
the population aged 25 years or over. Sample
stratification was by site and rural versus urban areas. Screening for hypertension was
conducted at six government primary health
clinics for either patients or accompanying
family members. The study was approved
and funded by clinical research committee at
Al-Quds University and by the Palestinian
American Research Council committee. The
researchers explained the nature and purpose
of the study, and obtained consent from those
who were willing to participate. Respondents
were assured of the anonymity and confidentiality of the study and their right not to participate or withdraw from the study at any
time.
DATA COLLECTION
During clinic visits, a standard questionnaire was administered by trained research
staff. Demographic information including
age, gender, education, occupation, and
smoking status was collected. In addition, the
questionnaire also included questions about
diagnosis and treatment of hypertension. Information was collected on disease awareness, drug treatment and lifestyle modification to manage hypertension. Each participant had two BP measurements by trained
and certified observers, according to protocol
adapted from procedures recommended by
the American Heart Association (AHA) (19].
The two BP measurements were taken with
an interval of 3 min apart. Respondents were
informed of their BP measurements. A standardized mercury sphygmomanometer was
used, and one of the three cuff sizes (small,
regular or large) was chosen on the basis of
the circumference of the participant’s arm.
The cuff was placed on the respondent’s right
arm 2–3 cm above the antecubital fossa. The
research supervisors conducted weekly
checks on compliance with BP measurement
protocol. A subject was considered hypertensive if: average SBP ≥140mmHg, or average
DBP ≥ 90mmHg and/or if patient self-
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reported treatment for hypertension with antihypertensive medication. Control of hypertension is defined as pharmacological treatment of hypertension associated with an average SBP <140mmHg and DBP <90mmHg.
Treatment of hypertension is defined as the
use of a prescription medication for management of high BP at the time of interview
(20).
Adherence to antihypertensive drugs was
measured by Morisky scale. The Morisky
scale is a valid self-report adherence measure
with four questions about common barriers to
adherence (21); 1) Do you ever forget to take
your prescription drugs? 2) Are you careless
at times about taking your drugs? 3) Do you
sometimes stop taking your drugs when you
feel better? 4) Do you sometimes stop taking
your drugs if they make you feel worse? All
patients who answered “yes” to at least two
of the four questions were classified as non
adherent.
Data were collected and analyzed using
the statistical package for social sciences
(SPSS) version 17. The chi -square test was
used to compare categorical variables like
non-adherent, education level and smoking
status in the two groups of controlled and
uncontrolled hypertensives. Univariate associations were tested by placing each variable
into a separate proportional odds model. For
categorical variables, referent variables were
created.
The proportional odds assumption was
not violated for any variables on univariate
analysis at a P value ≤0.05. Variables that
were associated with the above-defined outcomes at a P value <0.2 were entered into the
multivariate model. Variables with a P value
≤0.05 were kept in the final multivariate
model, as were gender and site of care. We
also examined interaction terms for potential
entry into the model.
RESULTS
The study data indicates that 27.6%
(573/2077) of Palestinian adult population
aged 25 years and over had hypertension
(Table 1, Ref 14). The prevalence of hypertension increased with age in both men and

women. Prevalence of hypertension was
higher among men than among women (29.2
vs 26.4% although the difference was not
significant (P>0.05). Prevalence of hypertension was slightly higher in urban than in rural
areas, but the difference was not significant
(28.2 and 26.6%, respectively; P=0.08).
The Mean age of hypertensive patients
was 57.5 ± 9.7 years. The mean systolic
blood pressure was 149 ± SD12 mm Hg
while the mean diastolic blood pressure was
91.2 ± SD 9 mm Hg. Only 33.2% (190/573)
of patients had mean blood pressure < 140/90
mm Hg (i.e. controlled hypertension).
Table (1): Prevalence of hypertension* in
adult population, aged 25 years and over in
West-Bank, Palestine.
Age
(year)
25-44

45-64
≥65
Total

Men n
(%)
(17.0)
63
134
(34.3)
58
(52.3)
255
(29.2)

Residence
Urban
167
(29.6)
Rural
88
(28.2)
Total
255
(29.2)

Women n
Total n
(%)
(%)
78(16.7)
141
(16.8)
155(27.6) 289
(30.3)
85(48.3)
143(49.8)
318
(26.4)

573
(27.6)

207
(27.1)
112
(25.3)
318
(26.4)

373
(28.2)
200
(26.6)
573
(27.6)

* Ref. 14

The characteristics’ of controlled and
uncontrolled hypertensives were summarized
in Table 2. There were no significant differences between controlled and uncontrolled
hypertensives in sex distribution, marital status, occupational status, educational level and
cigarette smoking. On univariate analysis, we
found the following characteristics to be associated with poor blood pressure control
(Table 3): older age > 65 years, being on
monotherapy for hypertension, being overweight or obese, lack of knowledge of appropriate target BP, and experience of an adverse effect of an antihypertensive medication.
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Table (2): Distribution of controlled (CH)
and uncontrolled hypertension (UCH) among
previously diagnosed hypertensive subjects
by selected variables (N=573).
Variable

CH n (%)

Total
190 (33.2)
Gender
Male
101(53.2)
Female
89(46.8)
Age (Years)
25-44
48(25.3)
45-64
90(47.4)
≥ 65
52(27.3)
Residence
Urban
121(63.7)
Rural
69(36.3)
Marital Status
Single
41(21.6)
Married
130(68.4)
Widowed
19(10.0)
Number of Medications
0
11(5.8)
1
115(60.5)
2
55(28.9)
≥3
9(4.7)
Education
Illiterate
22(11.6)
Primary and sec92(48.4)
ondary school
High school and
76(40.0)
above
Weight status
Normal (18.5≤
75(39.5)
BMI <23)
Overweight
100(52.6)
(23≤BMI<25)
Obese (BMI≥25)
15(7.9)
Co-morbidity*
98(51.6)
Reported side ef33(17.4)
fects attributed to
antihypertensive
medication
Lack of
84(44.2)
knowledge of target BP
On monotherapy
88(46.3)
for hypertension

UCH n
(%)
383 (66.8)
210(54.8)
173(45.2)
43(11.2)
217(56.7)
123(32.1)
239(62.4)
(36.5)
50(13.0)
268(70.0)
65(17.0
55(14.4)
190(49.6)
90(23.5)
48(12.5)
73(19.0)
199(52.0)
111(29.0)
90(23.5)
218(56.9)
75(19.6)
171(44.6)
111(29.0)

190(49.6)
157(40.9)

*These included other cardiovascular diseases;
Angina, Myocardial Infarction Heart Failure and
stroke

Table (3): Univariate Predictors of Poor
Blood Pressure Control*
Variable

Odds of
Poor
control

95% Confidence
Intervals

Gender
Male
1.66
1.19-2.36
Female
Reference
Age (Years)
25-44
Reference
45-64
1.53
1.19-1.83
≥ 65
2.33
1.29-3.88
Residence
Urban
0.92
0.57-1.44
Rural
Reference
Marital Status
Single
1.08
0.89-1.28
Married
Reference
Widowed
1.3
0.99-1.67
Education
Illiterate
0.98
0.67-1.19
Primary and secReference
ondary school
High school and
0.78
0.51-0.99
above
Weight status
Normal (18.5≤
Reference
BMI <23)
Overweight
1.64
1.23-1.88
(23≤BMI<25)
Obese (BMI≥25) 2.75
2.31-3.14
Adherence to antihypertensive drugs
Adherent
Reference
Non-Adherent
2.91
2.67-3.14
Co-morbidity
0.78
0.43-1.18
Reported side
1.88
1.23-2.34
effects attributed
to antihypertensive medication
Lack of
1.67
1.29-2.24
knowledge of
target blood pressure
On monotherapy
2.19
1.89-2.92
for hypertension
With construction of a multivariate model as described above, we found the following factors to be significantly and independently associated with poor blood pressure control after adjusting for all other sig-
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nificant predictors: being on monotherapy
regimen [OR=2.14, 95% CI 1.51-2.59], being
obese BMI >25 [OR=1.80, 95% CI 1.442.46], being non adherence to antihyperten-

sive drugs [OR=2.67, 95% CI 2.34-3.11],
older age > 65 [OR=2.12, 95% CI1.78-2.86]

Table (4): Multivariate Model of Poor Blood Pressure Control*
Odds of Poor control
Variable
Age (Years)
25-44
Reference
45-64
1.2
≥ 65
2.12
Number of Medications
0
0.76
1
Reference
2
1.98
≥3
2.77
Weight status
Normal (18.5≤ BMI <23)
Reference
Overweight (23≤BMI<25)
1.14
Obese (BMI≥25)
1.80
Adherence to antihypertensive drugs
Adherent
Reference
Non-Adherent
2.67
Co-morbidity
0.66
Reported side effects attributed to
1.67
antihypertensive medication
Lack of knowledge of target BP
1.21
On Monotherapy for hypertension
2.14

95% Confidence Intervals

0.89-1.44
1.78-2.86
0.59-0.96
1.61-2.34
2.14-3.10

0.98-1.33
1.44-2.16

2.34-3.11
0.42-0.99
1.29-1.97
1.11-1.87
1.51-2.59

*The odds ratio represents the likelihood of being in a higher blood pressure category. The model is adjusted
for gender

DISCUSSION
Hypertension is the most common and
most important risk factor for cardiovascular
disease (22-25). Improved control of hypertension, in turn, has contributed to reductions
in the incidence rates of stroke and ischemic
heart disease (26). Despite improvements in
the control of hypertension, there is evidence
that considerable numbers of people still
have uncontrolled high blood pressure (2728). Because morbidity and mortality are reduced in proportion to BP reduction, it is important to identify the major causes of failure
to control hypertension.
Only a small fraction (33.2%) of the 573
hypertensive patients evaluated had mean

blood pressure less than 140/90 mm Hg, despite ongoing medical treatment. The fact
that the majority of the hypertensive patients
had SBP higher than recommended is a
strong predictor of cardiovascular disease
with advancing age (29). Older age > 65
years was associated with poorer blood pressure control relative to that seen in younger
treated patients. Despite the proven benefits
of antihypertensive therapy in this age group,
older patients are still treated less aggressively compared with younger patients (29). The
clinical benefits of treating systolic hypertension in older patients have been demonstrated
in several randomized placebo controlled
trials (28-30).
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Another risk factor for poor blood pressure control was the lack of knowledge of
appropriate SBP in the univariate analysis.
Patients were significantly more likely to
have a higher mean blood pressure if they
indicated in the interview that they were not
aware that their target SBP should be <140
mm Hg. Such patients may be less likely to
see their physician if their blood pressure was
outside the ideal range, take their medication
or adopt healthy lifestyle changes. In some
controlled trials, educational interventions
have been shown to be effective in improving
blood pressure control (30). Educational interventions have also been shown to improve
compliance with blood pressure medication.

provides greater success at lowering blood
pressure and provides a better side-effect profile with smaller drug doses than is possible
with monotherapy.
Another potentially important observation was the relationship between poor blood
pressure control and adverse events attributed
to antihypertensive medications. In this study
some patients on Angiotensin Converting
Enzyme Inhibitors (ACEI) or calcium channel blockers for hypertension were more like
to adhere to therapy than patients prescribed
other antihypertensive drugs possibly because the former medications may have fewer side effects.

Like other economically developing
countries, the health care system in Palestine
faces a financial challenge. Although national
and international guidelines require blood
pressure to be measured during all outpatient
visits, it is still very common that no blood
pressure check-up is performed, especially in
rural area. In addition, community-based
blood pressure screening and education programs are uncommon in Palestine. Furthermore, clinicians are still used to treat only
patients with blood pressure 160/95 mm Hg.
Our findings highlight the need for developing a national high blood pressure education
program to coordinate the effort of detection,
prevention, and treatment of hypertension in
Palestine.

We found an association between nonadherence and poor control of hypertension,
which supports the findings of earlier studies
(31-32). It has been shown that adherence
decreases with an increasing number of daily
doses (33). Adherence improving strategies
are needed. This population of non-adherent
and uncontrolled hypertensives formed about
29.4% of our subjects and would be an ideal
target for health education. Information about
hypertension and its treatment is an important
way to increase patients’ motivation and understanding. It may be that patients with different levels of education have certain types
of reaction at the different stages of the disease and treatment concerning adherence.
This possible interaction should also be taken
into consideration in future studies (34).

The relationship between the number of
antihypertensive drugs used during the study
period and blood pressure control was studied. The active mechanism of blood pressurelowering drugs varies from agent to agent
and can be additive when combined appropriately. Unfortunately, combination therapy
is used infrequently in the management of
patients with hypertension. The current approach begins with lifestyle modifications
and monotherapy. Although a single drug
approach is ineffective in many patients, often the treatment regimen is not modified,
leading to inadequate control of blood pressure. Combination multidrug therapy usually

The results of this study showed a strong
correlation between poor hypertension control and obesity; BMI>25. Previous population-based studies suggest that the probability
of insufficient blood pressure control in
obese patients is about 50% higher than in
hypertensive patients with normal weight.
Around 50% of overweight and obese patients have been reported to be hypertensive,
the prevalence of hypertension increases further with higher grades of obesity (35). Similarly, almost 70% of hypertensive patients
have been reported to be overweight, with
more than 30% being obese (36-39).
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Poor control of obesity hypertension
may be related to its complex pathophysiologic effects on renal function and morphology. Obesity increases renal sodium reabsorption and impairs pressure natriuresis by activation of the renin-angiotensin and sympathetic nervous systems and by altered
intrarenal physical forces (40)
Patients with substantial comorbidity,
especially when blood pressure is a contributing factor, might be more likely to have
better blood pressure control because the impact of hypertension would be more apparent
to them compared with those with asymptomatic hypertension and no comorbidity.
However, in this study the co-morbidity contributing Non-significantly to poor control of
hypertension.
Several limitations of this study deserve
mention. Specifically, BP was measured 3
times following a standard protocol during
only a single visit. According to both World
Health Organization and National Institute of
Health guidelines, hypertension should be
defined based on the average of at least 2 or
more BP readings taken at 2 or more visits
after an initial screening. Another limitation
of the current study was the cross-sectional
study design and was confined to adults who
were 25 to 74 years old. The simple four
questions method for quantitating medication
compliance has potential shortcomings.
Therefore better methods for detection of
poor compliance need to be developed such
as the use of electronic devices. Also only the
goal SBP reading <140 or DBP < 90 consider
controlled hypertension regardless the presence co-morbidity.
CONCLUSION
Data provide further evidence that poor
blood pressure control is common in a variety of health care settings, and that patients at
particular risk of poor control can be identified. We recommend targeted interventions
to improve management in such patients
which could make a substantial difference in

stemming the epidemic of poorly controlled
hypertension in Palestine.
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